118 research outputs found
Landscape of Future blood testing in healthcare practice - Professor Dimitris Grammatopoulos (University of Warwick)
No full text<p>This video is the third talk from our Future of Healthcare: Remote Blood Testing, Monitoring & AI Meeting that took place on 07-08/11/2023. </p>
<p>Landscape of Future blood testing in healthcare practice – Professor Dimitris Grammatopoulos (University of Warwick). </p>
<p>Bio: Dimitris Grammatopoulos, PhD, FRCPath, is Professor of Molecular Medicine at Warwick Medical School and Consultant in Clinical Biochemistry and Molecular Diagnostics at the University Hospitals of Coventry and Warwickshire, NHS Trust, United Kingdom. He also leads the Novel Biomarkers theme of the Institute of Precision Diagnostics and Translational Medicine, Pathology-UHCW NHS Trust, where he combines clinical expertise in diagnostic laboratory medicine with a research track-record in application of cutting edge multidiscipline methodologies in routine clinical diagnostics. He received academic and clinical training in Newcastle, Bristol, Johns Hopkins-Baltimore and Warwick. He has expertise in biochemical/molecular diagnosis of many endocrine and metabolic disorders. His translational research interest is focused on stress hormones and homeostatic adaptations of fetal development to maternal disease as well as development of novel -omics based biomarker approaches suitable for precision medicine and better characterisation of patient phenotype. He has experience around use of AI and ML for development and refinement of clinical and diagnostic pathways for complex chronic conditions that are considered as national priorities. Dimitris is the Lead in Diagnostics, Global Health Priorities in Health, University of Warwick.</p>
<p>Further details on this event can be found at:<a href="https://futurebloodtesting.org/event/the-future-of-healthcare-remote-blood-testing-monitoring-ai/"> https://futurebloodtesting.org/event/the-future-of-healthcare-remote-blood-testing-monitoring-ai/</a></p>
<p>This video is an output from the Future Blood Testing Network which is funded by EPSRC under Grant Number EP/W000652/1</p>
<p>YouTube Link: <a href="https://www.youtube.com/watch?v=8tL9FEqIv6o&list=PL_5Zbof1GNkCZLgQwZnxsMTQUELUCQHlp&index=3">https://www.youtube.com/watch?v=8tL9FEqIv6o&list=PL_5Zbof1GNkCZLgQwZnxsMTQUELUCQHlp&index=3</a></p>
Transforming the UK's diagnostics agenda after COVID-19 and grand challenges – Future Blood Testing Landscape report - Prof Dimitris Grammatopoulos (University Hospitals Coventry & Warwickshire, University of Warwick)
No full textThis video is the second talk from our two day Future Blood Testing: Challenges & Opportunities Event that took place on the 13/09/2022.
Transforming the UK’s diagnostics agenda after COVID-19 and grand challenges – Future Blood Testing Landscape report - Prof Dimitris Grammatopoulos (University Hospitals Coventry & Warwickshire, University of Warwick)
Bio: Dimitris Grammatopoulos, PhD, FRCPath, is Professor of Molecular Medicine at Warwick Medical School and Consultant in Clinical Biochemistry and Molecular Diagnostics at the University Hospitals of Coventry and Warwickshire, NHS Trust, United Kingdom. He also leads the Novel Biomarkers theme of the Institute of Precision Diagnostics and Translational Medicine, Pathology-UHCW NHS Trust. where he combines clinical expertise in diagnostic laboratory medicine with a research track-record in application of cutting edge multidiscipline methodologies in routine clinical diagnostics. He received academic and clinical training in Newcastle, Bristol, Johns Hopkins-Baltimore and Warwick. He has expertise in biochemical/molecular diagnosis of many endocrine and metabolic disorders. His translational research interest is focused on stress hormones and homeostatic adaptations of fetal development to maternal disease as well as development of novel -omics based biomarker approaches suitable for precision medicine and better characterisation of patient phenotype. He has experience around use of AI and ML for development and refinement of clinical and diagnostic pathways for complex chronic conditions that are considered as national priorities. Dimitris is the Lead in Diagnostics, Global Health Priorities in Health, University of Warwick.
Further details on this event can be found at: https://futurebloodtesting.org/event/13-14-09-2022/
This video is an output from the Future Blood Testing Network which is funded by EPSRC under Grant Number EP/W000652/1
YouTube Link: https://youtu.be/HiOlRzJPR7
FERRIQ: AI-Driven mapping of disease trajectories – Dr Fayyaz Minhas & Prof Dimitris Grammatopoulos
No full text<p>This video is the fifth talk from our Future of Healthcare: Remote Blood Testing, Monitoring & AI Meeting that took place on 07-08/11/2023. </p>
<p>FERRIQ: AI-Driven mapping of disease trajectories of patients with genetic iron overload to inform development of clinical decision support systems – Dr Fayyaz Minhas & Professor Dimitris Grammatopoulos (University of Warwick). </p>
<p>Bios: Fayyaz Minhas is an associate professor at Warwick Department of Computer Science. He is also the Deputy Director of the Tissue Image Analytics (TIA) centre and is affiliated with the Pathology image data Lake for Analytics, Knowledge and Education (PathLAKE) consortium. He is a recipient of the Fulbright scholarship and works on solving problems in biology and medicine using machine learning methods as well as the development of bespoke machine learning algorithms in the domains of biomedical informatics, computational pathology, bioinformatics and data science. Specifically, he is interested in designing machine learning models for integrating digital pathology and bioinformatics data for improved diagnosis and therapeutics. </p>
<p>Dimitris Grammatopoulos, PhD, FRCPath, is Professor of Molecular Medicine at Warwick Medical School and Consultant in Clinical Biochemistry and Molecular Diagnostics at the University Hospitals of Coventry and Warwickshire, NHS Trust, United Kingdom. He also leads the Novel Biomarkers theme of the Institute of Precision Diagnostics and Translational Medicine, Pathology-UHCW NHS Trust, where he combines clinical expertise in diagnostic laboratory medicine with a research track-record in application of cutting edge multidiscipline methodologies in routine clinical diagnostics. He received academic and clinical training in Newcastle, Bristol, Johns Hopkins-Baltimore and Warwick. He has expertise in biochemical/molecular diagnosis of many endocrine and metabolic disorders. His translational research interest is focused on stress hormones and homeostatic adaptations of fetal development to maternal disease as well as development of novel -omics based biomarker approaches suitable for precision medicine and better characterisation of patient phenotype. He has experience around use of AI and ML for development and refinement of clinical and diagnostic pathways for complex chronic conditions that are considered as national priorities. Dimitris is the Lead in Diagnostics, Global Health Priorities in Health, University of Warwick. </p>
<p>Further details on this event can be found at: <a href="https://futurebloodtesting.org/event/the-future-of-healthcare-remote-blood-testing-monitoring-ai/">https://futurebloodtesting.org/event/the-future-of-healthcare-remote-blood-testing-monitoring-ai/</a></p>
<p>This video is an output from the Future Blood Testing Network which is funded by EPSRC under Grant Number EP/W000652/1</p>
<p>YouTube Link: <a href="https://www.youtube.com/watch?v=GsAyoVTLYdc&list=PL_5Zbof1GNkCZLgQwZnxsMTQUELUCQHlp&index=4">https://www.youtube.com/watch?v=GsAyoVTLYdc&list=PL_5Zbof1GNkCZLgQwZnxsMTQUELUCQHlp&index=4</a></p>
Corticotropin-releasing factor receptors couple to multiple g-proteins to activate diverse intracellular signaling pathways in mouse hippocampus: role in neuronal excitability and associative learning
No full textCorticotropin-releasing factor (CRF) exerts a key neuroregulatory control on stress responses in various regions of the mammalian brain, including the hippocampus. Using hippocampal slices, extracts, and whole animals, we investigated the effects of human/rat CRF (h/rCRF) on hippocampal neuronal excitability and hippocampus-dependent learning in two mouse inbred strains, BALB/c and C57BL/6N. Intracellular recordings from slices revealed that application of h/rCRF increased the neuronal activity in both mouse inbred strains. Inhibition of protein kinase C (PKC) by bisindolylmaleimide I (BIS-I) prevented the h/rCRF effect only in hippocampal slices from BALB/c mice but not in slices from C57BL/6N mice. Inhibition of cAMP-dependent protein kinase (PKA) by H-89 abolished the h/rCRF effect in slices from C57BL/6N mice, with no effect in slices from BALB/c mice. Accordingly, h/rCRF elevated PKA activity in hippocampal slices from C57BL/6N mice but increased only PKC activity in the hippocampus of BALB/c mice. These differences in h/rCRF signal transduction were also observed in hippocampal membrane suspensions from both mouse strains. In BALB/c mice, hippocampal CRF receptors coupled to Gq/11 during stimulation by h/rCRF, whereas they coupled to Gs, Gq/11, and Gi in C57BL/6N mice. As expected on the basis of the slice experiments, h/rCRF improved context-dependent fear conditioning of BALB/c mice in behavioral experiments, and BIS-I prevented this effect. However, although h/rCRF increased neuronal spiking in slices from C57BL/6N mice, it did not enhance conditioned fear. These results indicate that the CRF system activates different intracellular signaling pathways in mouse hippocampus and may have distinct effects on associative learning depending on the mouse strain investigated
Author Correction:Genomic epidemiology reveals multiple introductions of SARS-CoV-2 from mainland Europe into Scotland (Nature Microbiology, (2021), 6, 1, (112-122), 10.1038/s41564-020-00838-z)
No full textCorrection to: Nature Microbiology https://doi.org/10.1038/s41564-020-00838-z, published online 21 December 2020.In the Supplementary Information PDF originally published with this Article, the surname of the consortium member Dimitris Grammatopoulos was misspelt ‘Gramatopoulos’. This error has now been corrected.</p
Recommended from our members
[Correction] Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies (Nature, (2021), 593, 7857, (136-141), 10.1038/s41586-021-03412-7)
No full textIn the version of this article initially published, the surname of a member of the COVID-19 Genomics UK (COG-UK) Consortium was misspelt as Gramatopoulos. The correct spelling is Dimitris Grammatopoulos. The name has been corrected in the HTML and PDF versions of the article.</p
Recommended from our members
[Correction] SARS-CoV-2 evolution during treatment of chronic infection (Nature, (2021), 592, 7853, (277-282), 10.1038/s41586-021-03291-y)
No full textIn the version of this article initially published, the surname of a member of The COVID-19 Genomics UK (COG-UK) Consortium was misspelt as Gramatopoulos. The correct spelling is Dimitris Grammatopoulos. The name has been corrected in the HTML and PDF versions of the article.</p
The onset of labor alters corticotropin-releasing hormone type 1 receptor variant expression in human myometrium : putative role of interleukin-1ß
No full textCRH targets the human myometrium during pregnancy. The efficiency of CRH actions is determined by expression of functional receptors (CRH-R), which are dynamically regulated. Studies in myometrial tissue biopsies using quantitative RT-PCR demonstrated that the onset of labor, term or preterm, is associated with a significant 2- to 3-fold increase in CRH-R1 mRNA levels. Detailed analysis of myometrial CRH-R1 mRNA variants showed a decline of the pro-CRH-R1 mRNA encoding the CRH-R1ß variant during labor and increased mRNA levels of CRH-R1d mRNA. Studies in myometrial cells identified IL-1ß as an important regulator of myometrial CRH-R1 gene expression because prolonged treatment of myometrial cells with IL-1ß (1 ng/ml) for 18 h induced expression of CRH-R1 mRNA levels by 1.5- to 2-fold but significantly attenuated CRH-R1ß mRNA expression by 70%. In contrast, IL-1ß had no effect on CRH-R1d mRNA expression. Studies using specific inhibitors suggest that ERK1/2, p38 MAPK, and downstream nuclear translocation of nuclear factor-B mediate IL-1ß effects on myometrial CRH-R1 gene. However, the increased CRH-R1 mRNA expression was associated with a dampening of the receptor efficacy to activate the adenylyl cyclase/cAMP signaling cascade. Thus, our findings suggest that IL-1ß is an important regulator of CRH-R1 expression and functional activity, and this interaction might play a role in the transition of the uterus from quiescence to active contractions necessary for the onset of parturition
Identification of a novel corticotropin-releasing hormone type 1 beta-Like receptor variant lacking exon 13 in human pregnant myometrium regulated by estradiol-17 beta and progesterone
No full textTwo types of CRH receptors mediate the diverse biological functions of CRH and CRH-related peptides. The type 1 CRH-R (CRH-R1) is extensively targeted by pre-mRNA splicing mechanisms that give rise to multiple mRNA splice variants. RT-PCR amplification of CRH-R1 sequences from human myometrium yielded cDNAs that encode a novel CRH-R1 splice variant with structural characteristics identical with CRH-R1 beta except a 14-amino acid deletion in the seventh transmembrane domain characteristic of the CRH-R1d. Transient expression of the hybrid CRH-R1 variant (CRH-R1 beta/d) in human embryonic kidney 293 cells revealed primarily intracellular expression, although some plasma membrane protein expression was also detectable. CRH bound to CRH-R1 beta/d with affinity comparable with the CRH-R1 beta; however, it was unable to stimulate adenylyl cyclase or other second messengers. Using a semiquantitative RT-PCR assay, CRH-R1 beta/d mRNA transcript was detected in human pregnant, but not nonpregnant, myometrium as early as 31 wk of gestation. Furthermore, in human pregnant myometrial cells, the relative expression of CRH-R1 beta and CRH-R1 beta/d mRNA appeared to be regulated by steroids; CRH-R1 beta/d mRNA expression was increased by estradiol-17 beta, whereas CRH-R1 beta mRNA levels were increased by progesterone. Progesterone also substantially increased CRH-R1 alpha mRNA levels and cellular responsiveness to CRH as determined by increased agonist binding and cAMP production as well as resistance to CRH-R heterologous desensitization by phorbol esters. These results provide novel evidence for distinct patterns of CRH-R1 splicing and identify specific steroid-mediated regulation of CRH-R1 variant expression, which might be important for modulating CRH actions during human pregnancy and labour. (Endocrinology 151: 4959-4968, 2010
- …
